数量	产品目录编号	订购说明	数量 / 包装	公开价
			96-Well Plate

数量	产品目录编号	订购说明	数量 / 包装	公开价
	48-602MAG	Buffer Detection Kit for Magnetic Beads	1 Kit

554723 Sigma-AldrichATRA-BA Hybrid - CAS 1037543-26-2 - Calbiochem

The differentiation-inducer all-trans-Retinoic Acid and the histone deacetylase inhibitor (HDI) Butyric Acid.

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

MSDS
分析证书
参考
技术信息
Data Sheet

同义词: 4-(Butanoyloxymethyl)phenyl-(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoate, VNLG/124, HDAC Inhibitor XV

Recommended Products

概述

Replacement Information

重要规格表

CAS #	Empirical Formula
1037543-26-2	C₃₁H₄₀O₄

价格及供货情况

产品目录编号	库存情况	包装	数量 / 包装	价格	数量
554723-25MGCN	正在查询供货情况...... — 目前缺货有货停产少量现货供货情况有待确认登录查看库存有货目前缺货有货其余：另行通知其余：另行通知另行通知联系客户服务 Contact Customer Service 联系客户服务联系客户服务	塑胶安瓿;塑胶针药瓶	25 mg	正在检索价格...... 无法检索价格。最小订购数量为倍数 Maximum Quantity is 以订单确认为准更多信息您节约了 ()。 — Request Pricing 登录查看价格	查看库存情况 —	添加到收藏夹添加到收藏夹添加到我的收藏夹

Description
Overview	The differentiation-inducer all-trans-Retinoic Acid (ATRA; Cat. No. 554720) and the histone deacetylase inhibitor (HDI) Butyric Acid (BA; Cat. No. 567430) are incorporated chemically via a benzyl ester linkage into a single more permeant mutual prodrug (MP) to facilitate their cellular uptake and to better synergize their cancer killing potency. The growth inhibitions of PC-3 and MDA-MB-231 by the MP (IC₅₀ = 1.02 and 0.01 µM, respectively) are much superior to those achieved by separate (IC₅₀ = 7.6 and 10.85 µM, respectively, with ATRA; IC₅₀ = 72.44 and >1000 µM, respectively, with BA) or combined dosing of ATRA/BA (55% vs. 30% PC-3 growth inhibition by 10 µM MP vs. co-treatment of 10 µM each of ATRA & BA). At 37°C, VNLG/124 is completely converted to ATRA and BA within an hour in fresh murine plasma, but is otherwise stable for more than 24 hours in the absence of esterase activity in 20 mM PBS.
Catalogue Number	554723
Brand Family	Calbiochem®
Synonyms	4-(Butanoyloxymethyl)phenyl-(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoate, VNLG/124, HDAC Inhibitor XV

References
References	Gediya, L.K., et al. 2008. J. Med. Chem. 51, 3895.

Product Information
CAS number	1037543-26-2
Form	Yellow solid
Hill Formula	C₃₁H₄₀O₄
Chemical formula	C₃₁H₄₀O₄
Structure formula Image
Quality Level	MQ100

Applications

Biological Information
Purity	≥95% by HPLC

Physicochemical Information

Dimensions

Materials Information

Toxicological Information

Safety Information according to GHS

Safety Information
R Phrase	R: 22-36/37/38-63 Harmful if swallowed. Irritating to eyes, respiratory system and skin. Possible risk of harm to the unborn child.
S Phrase	S: 22-26-36-45 Do not breathe dust. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing. In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).

Product Usage Statements

Storage and Shipping Information
Ship Code	Shipped with Blue Ice or with Dry Ice
Toxicity	Harmful
Storage	-20°C
Protect from Light	Protect from light
Protect from Moisture	Protect from moisture
Do not freeze	Ok to freeze
Special Instructions	Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.

Packaging Information
Packaged under inert gas	Packaged under inert gas

Transport Information

Supplemental Information

Specifications

Global Trade Item Number
产品目录编号	GTIN
554723-25MGCN	04055977193138

Documentation

ATRA-BA Hybrid - CAS 1037543-26-2 - Calbiochem MSDS

职位
物料安全数据表 (MSDS)

ATRA-BA Hybrid - CAS 1037543-26-2 - Calbiochem 分析证书

标题	批号
554723	输入批号

参考

参考信息概述
Gediya, L.K., et al. 2008. J. Med. Chem. 51, 3895.

技术信息

标题
White Paper - The Message in the Marks: Deciphering Cancer Epigenetics

数据表

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision	28-April-2009 RFH
Synonyms	4-(Butanoyloxymethyl)phenyl-(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoate, VNLG/124, HDAC Inhibitor XV
Description	The differentiation-inducer all-trans-Retinoic Acid (ATRA; Cat. No. 554720) and the histone deacetylase inhibitor (HDI) Butyric Acid (BA; Cat. No. 567430) are incorporated chemically via a benzyl ester linkage into a single more permeant mutual prodrug (MP) to facilitate their cellular uptake and to better synergize their cancer killing potency. The growth inhibitions of PC-3 and MDA-MB-231 by the MP (IC₅₀ = 1.02 and 0.01 µM, respectively) are much superior to those achieved by separate (IC₅₀ = 7.6 and 10.85 µM, respectively, with ATRA; IC₅₀ = 72.44 and >1000 µM, respectively, with BA) or combined dosing of ATRA/BA (55% vs. 30% PC-3 growth inhibition by 10 µM MP vs. co-treatment of 10 µM each of ATRA & BA). At 37°C, VNLG/124 is completely converted to ATRA and BA within an hour in fresh murine plasma, but is otherwise stable for more than 24 hours in the absence of esterase activity in 20 mM PBS.
Form	Yellow solid
Intert gas (Yes/No)	Packaged under inert gas
CAS number	1037543-26-2
Chemical formula	C₃₁H₄₀O₄
Structure formula
Purity	≥95% by HPLC
Solubility	DMSO (5 mg/ml)
Storage	Protect from moisture Protect from light -20°C
Do Not Freeze	Ok to freeze
Special Instructions	Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
Toxicity	Harmful
References	Gediya, L.K., et al. 2008. J. Med. Chem. 51, 3895.

种类

Life Science Research > Inhibitors and Biochemicals > Small Molecules & Inhibitors > Anticancer Agents

此产品已添加到您的购物车。